Biopharma Files New Drug Application for Lead Clinical Product

Source: Streetwise Reports   07/07/2021

A review of Daré Bioscience’s lead clinical product for bacterial vaginosis and a potential timeline to commercialization are provided in a Roth Capital Partners report.

In a July 1 research note, Roth Capital Partners analyst Zegbeh Jallah reported that the women’s health biopharma Daré Bioscience Inc. (DARE:NASDAQ) filed a new drug application with the U.S. Food and Drug Administration (FDA) for its lead candidate DARE-BV1, for bacterial vaginosis.

Given the drug’s fast track and qualified infectious disease designations, FDA review should be a priority, Jallah purported, with the agency issuing a decision on acceptance and a Prescription Drug User Fee Act (PDUFA) date in about August 2021. If the FDA subsequently approves the drug, that would happen around late 2021, with a commercial launch following in the first half of 2022.

Jallah reiterated that the bacterial vaginosis market is sizable, with about 21 million women in the U.S. alone experiencing this recurrent infection.

Phase 3 data for DARE-BV1, a single application vaginal gel of clindamycin, were positive, Jallah indicated. They showed statistically significant cure rates of 70% versus 36% for placebo (p<0.001) between days 21 and 30, with cures evident between days 7 and 14. DARE-BV1’s demonstrated cure rate is better than the 30–68% cure rate with other FDA approved treatments such as metronidazole, and those require multiple applications.

“Thus, DARE-BV1 remains largely differentiated in its efficacy and convenience,” Jallah wrote.

Daré intends to partner with another company to commercialize DARE-BV1 to the market, and discussions on that front are taking place, Jallah noted. Three prospective partners are Pfizer, which already has a clindamycin product; Organon, which wants to expand its bacterial vaginosis program; and Bayer, which already partners with Daré for Ovaprene.

Roth has a Buy rating on Daré Bioscience and an $11 price target. The stock is trading at about $1.93 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from ROTH Capital Partners, Dare Bioscience Inc., Company Note, July 1, 2021

Regulation Analyst Certification (“Reg AC”): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

ROTH makes a market in shares of Daré Bioscience, Inc. and as such, buys and sells from customers on a principal basis.
Shares of Daré Bioscience, Inc. may be subject to the Securities and Exchange Commission’s Penny Stock Rules, which
may set forth sales practice requirements for certain low-priced securities.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.